Solutions for
Difficult-to-Treat Cancers
FLAG Therapeutics is a near-term clinical stage company focused on developing new small molecule therapeutics for difficult-to-treat cancers. FLAG-003, the company’s lead candidate for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG - a rare and fatal pediatric cancer) and glioblastoma multiform (GBM), is on-track to enter Phase 1 clinical development in early 2025 in children with DIPG.
Recent News / Events
July 16, 2024
Click here to view related abstract and poster
21st International Symposium on Pediatric Neuro-Oncology
Poster DIPG68: FLAG-003, A NOVEL, DUAL-ACTION THERAPEUTIC, DEMONSTRATES IN-VITRO ACTIVITYAGAINST DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
July 1, 2024